A Randomized, Multicenter, Open-label, Phase III Trial comparing Trastuzumab plus Pertuzumab plus a Taxane following Anthracyclines versus Trastuzumab Emtansine plus Pertuzumab following Anthracyclines as Adjuvant Therapy in Patients with Operable HER 2 Positive Primary Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Nov 2017
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Anthracyclines; Docetaxel; Paclitaxel; Pertuzumab; Trastuzumab
- Indications Early breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms KAITLIN
- Sponsors Chugai Pharmaceutical; Roche
- 24 Feb 2017 Planned End Date changed from 1 May 2023 to 1 Jan 2024.
- 24 Feb 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Jan 2024.
- 19 Nov 2015 Planned number of patients changed from 2500 to 1846 as per ClinicalTrials.gov record.